DDInter1348 DDInter1435
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Orlistat {u} (Compound) resembles {v} (Compound) Ethanolamine Oleate
Orlistat {u} (Compound) resembles {v} (Compound) Sodium Tetradecyl Sulfate
Orlistat {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Orlistat {u} (Compound) binds {v} (Gene) DAGLA
Orlistat {u} (Compound) upregulates {v} (Gene) SCD
Orlistat {u} (Compound) is included by {v} (Pharmacologic Class) Lipase Inhibitors
Orlistat {u} (Compound) downregulates {v} (Gene) AKR1B10
Orlistat {u} (Compound) causes {v} (Side Effect) Otitis
Orlistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholecalciferol
Orlistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxercalciferol
Orlistat (Compound) resembles Ethanolamine Oleate (Compound)
Orlistat (Compound) resembles Sodium Tetradecyl Sulfate (Compound)
Orlistat (Compound) treats type 2 diabetes mellitus (Disease)
Orlistat (Compound) binds DAGLA (Gene)
Orlistat (Compound) upregulates SCD (Gene)
Orlistat (Compound) is included by Lipase Inhibitors (Pharmacologic Class)
Orlistat (Compound) downregulates AKR1B10 (Gene)
Orlistat (Compound) causes Otitis (Side Effect)
Orlistat may cause a minor interaction that can limit clinical effects when taken with Cholecalciferol
Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol